Clone:
REAL1094
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
CD20cy, CD20 cytoplasmic domain

Specifications for CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™

Overview

Clone REAL1094 is an antibody fragment derived from the full CD20 Cytoplasmic antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL1094 recognizes an intracytoplasmic epitope localized on the CD20 antigen, which is a non-glycosylated transmembrane protein of 33–37 kDa that is expressed on B lineage cells from the pre–B cell stage to the B cell lymphoblast stage. The antigen is also expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca2
+
channel and might function in the regulation of local responses during B cell activation. In vitro effects of CD20-specific antibodies on resting B cells indicate that CD20 is able to transduce an extracellular signal affecting the G0/G1 cell cycle transition. Studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

CD20cy, CD20 cytoplasmic domain

Detailed product information

Technical specifications

CloneREAL1094
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD20 Cytoplasmic
Alternative names of antigenCD20cy, CD20 cytoplasmic domain
Distribution of antigenB cells, spleen

References for CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™

Publications

  1. Einfeld, D. A. et al. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7(3): 711-717
  2. Deans, J. P. et al. (1995) Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J. Biol. Chem. 270(38): 22632-22638
  3. Mishima, Y. et al. (2011) The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J. 1(4): e15
  4. Vaughan, A. T. et al. (2015) Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J. Biol. Chem. 290(9): 5424-5437
  5. Shanehbandi, D. et al. (2017) CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies. Curr. Cancer Drug Targets 17(5): 423-444

Seems like you are coming from USA!
Do you want to visit our website in your country?